UNC Lineberger, Gillings Biostatistics, and the Translational Breast Cancer Research Consortium have launched the ARPA-H ADAPT platform for metastatic breast cancer. Dr. Naim Rashid co-leads the analytics core, providing a Bayesian adaptive design that uses longitudinal ctDNA, imaging, and clinical data in real time. The study will enroll participants across partner sites beginning in 2025.

Gillings News coverage: “ARPA-H awards $28M to UNC team to build adaptive breast cancer trial”.